Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEFEND: AMG 162 (denosumab) for prevention of postmenopausal osteoporosis
NCT00091793Phase 3Completed
- Sponsor
- Amgen
- Start
- Aug 2004
- Primary completion
- Feb 2009
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
01
Overview
Phase 3, randomised, double-blind trial in postmenopausal osteoporosis comparing AMG 162 with Placebo (2 arms). Primary endpoint: Lumbar Spine Bone Mineral Density Percent Change From Baseline at 24 months. Started Aug 2004; status: completed.
02
Drugs
denosumab
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT00091793.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00091793.